Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone317-276-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.56 billion
Profitability
Miscellaneous
Employees38,680
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co announced a quarterly dividend on Tuesday, June 18th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.645 per share on Tuesday, September 10th. This represents a $2.58 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend is Wednesday, August 14th. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) released its quarterly earnings data on Tuesday, July, 30th. The company reported $1.50 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The firm's revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.48 EPS. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
How can I listen to Eli Lilly And Co's earnings call?
Eli Lilly And Co will be holding an earnings conference call on Wednesday, October 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY19 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $5.67-5.77 for the period, compared to the Thomson Reuters consensus estimate of $5.66. The company issued revenue guidance of $22-22.5 billion, compared to the consensus revenue estimate of $22.18 billion.
What price target have analysts set for LLY?
16 brokerages have issued 1-year target prices for Eli Lilly And Co's stock. Their forecasts range from $74.51 to $143.00. On average, they expect Eli Lilly And Co's stock price to reach $123.1227 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter. However, Lilly lowered its sales guidance for 2019. Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)
Has Eli Lilly And Co been receiving favorable news coverage?
Media headlines about LLY stock have been trending negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eli Lilly And Co earned a news impact score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Eli Lilly And Co.
Are investors shorting Eli Lilly And Co?
Eli Lilly And Co saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 11,459,200 shares, a decrease of 6.2% from the June 30th total of 12,215,500 shares. Based on an average daily trading volume, of 4,080,000 shares, the short-interest ratio is currently 2.8 days. Approximately 1.3% of the shares of the stock are sold short. View Eli Lilly And Co's Current Options Chain.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).
What other stocks do shareholders of Eli Lilly And Co own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Intel (INTC), AT&T (T), General Electric (GE), Exxon Mobil (XOM), Cisco Systems (CSCO), Gilead Sciences (GILD) and Bank of America (BAC).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
- Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
- Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.37%), BlackRock Inc. (6.42%), Primecap Management Co. CA (4.47%), Northern Trust Corp (1.15%), Price T Rowe Associates Inc. MD (0.89%) and Bank of New York Mellon Corp (0.82%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, Jennison Associates LLC, Jennison Associates LLC, Schroder Investment Management Group, Morgan Stanley, Nomura Holdings Inc. and Investec Asset Management LTD. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, Grantham Mayo Van Otterloo & Co. LLC, AQR Capital Management LLC, BlackRock Inc., Thoroughbred Financial Services LLC, Amundi Pioneer Asset Management Inc. and Vanguard Group Inc.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and Joshua L Smiley. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $110.52.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $106.70 billion and generates $24.56 billion in revenue each year. The company earns $3.23 billion in net income (profit) each year or $5.55 on an earnings per share basis. Eli Lilly And Co employs 38,680 workers across the globe.View Additional Information About Eli Lilly And Co.
What is Eli Lilly And Co's official website?
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
